XORTX Therapeutics Inc. XRTX
Set alert
As of Nov 2, 12:15 PM ET
- YTD
- -62.81%
- 1 year
- -65.40%
- Open
- 1.05
- Prev close
- 1.00
- Mkt cap
- 1.90M
- Vol
- 5.49K
- Avg vol
- 723.02K
- EPS
- -2.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.02
- High
- 1.05
- Forward P/E
- -0.67
- Beta
- -0.21
- Short ratio
- 0.02
- Inst. own
- 6.03%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.37
- 200-d avg
- 2.14
- 1y target
- 0.00
1M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Nov 2, 2026 | 2 hours ago |
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
Key statistics
- Market cap
- 3.61M
- Enterprise value
- 744.15K
- Trailing P/E
- 9.33
- Forward P/E
- -0.67
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.48
- EPS (TTM)
- 0.12
- Beta
- -0.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.85M
- Total cash
- 3.08M
- Total debt
- 83.71K
- Return on equity
- -29.36%
- Shares outstanding
- 3.22M
- Short % of float
- 0.07%
- 50-day average
- 1.37
- 200-day average
- 2.14
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.20 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.06 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -1.24 | — | — |
| Apr 2, 2024 | Dec 1, 2023 | 0.00 | -0.48 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -6.03 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.81 | — | — |
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- xortx.com
News
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
- 12 Health Care Stocks Moving In Friday's Intraday Session
- XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
Your note
Sign in to keep a note on XRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Davidoff, Allen Warren | Director of Issuer | Acquisition or disposition in the public market | Nov 10, 2022 | 440,917 |
| Keshri (Amar Deep) | Senior Officer of Issuer | Acquisition or disposition in the public market | Dec 1, 2021 | 8,500 |
| MacDonald (David) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Jan 19, 2022 | 20,000 |
| Pratt (Raymond Dennis M.D.) | Director of Issuer | Opening Balance-Initial SEDI Report | Jan 11, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.54% | 18,780 | 21.03K | Sep 29, 2024 |
| National Bank of Canada/FI | 0.10% | 3,440 | 3.85K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.03% | 1,153 | 1.29K | Sep 29, 2024 |
| Royal Bank of Canada | 0.02% | 672 | 752 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.01% | 254 | 284 | Sep 29, 2024 |
| Clearstead Advisors, LLC | 0.01% | 277 | 310 | Sep 29, 2024 |